On August 5, THE CIGNA GROUP fell 3.46% in regular trading, trading at approximately $270.97/share, with turnover of $61.59 million. The decline was triggered by Jefferies downgrading the stock from Buy to Hold, cutting its price target from $336 to $307, citing increasing earnings headwinds and a lack of clear catalysts.

This marks the second consecutive session of analyst downgrades. On August 4, Raymond James lowered its rating from Strong Buy to Outperform and reduced the target from $350 to $320, pointing to slowing business growth and persistent headwinds in the pharmacy benefit management segment. Both firms noted that while Q2 earnings beat estimates with adjusted EPS of $7.78 versus the $7.60 consensus, management confirmed during the earnings call that GLP-1 prescription growth is moderating, pressuring pharmacy operations.

The broader Health Care Services sector was under significant pressure, with CVS Health down 6.57% and DaVita HealthCare Partners down 17.54%, reflecting widespread weakness across managed care and health services names.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)